BioCentury
ARTICLE | Clinical News

MyeloXen: Phase I/IIa ongoing

December 15, 2014 8:00 AM UTC

Xenetic said Pharmsynthez completed dosing in a 3-part, open-label, Russian Phase I/IIa trial evaluating MyeloXen in 26 subjects. The first part enrolled 6 healthy volunteers, while the second and thi...